1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,150 | 9,650 | 18:31 | |
| 9,150 | 9,650 | 18:16 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.02. | MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia | 1 | GlobeNewswire (USA) | ||
| 08.01. | MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | 276 | GlobeNewswire (Europe) | Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free... ► Artikel lesen | |
| 02.01. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 20.11.25 | MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors | 1 | GlobeNewswire (USA) | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.11.25 | MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | 233 | GlobeNewswire (Europe) | New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive... ► Artikel lesen | |
| 14.11.25 | MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20 | 2 | Seeking Alpha | ||
| 07.11.25 | MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 | 236 | GlobeNewswire (Europe) | Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune... ► Artikel lesen | |
| 05.11.25 | MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development | 3 | GlobeNewswire (USA) | ||
| 30.10.25 | MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting | 3 | GlobeNewswire (USA) | ||
| 29.09.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09.25 | MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board | 2 | Investing.com | ||
| 29.09.25 | MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors | 11 | GlobeNewswire (USA) | ||
| 25.09.25 | MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | 2 | GlobeNewswire (USA) | ||
| 18.09.25 | MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development | 1 | GlobeNewswire (USA) | ||
| 15.08.25 | MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results | 4 | Investing.com | ||
| 14.08.25 | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | 238 | GlobeNewswire (Europe) | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| 14.07.25 | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | 371 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.07.25 | MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer | 184 | GlobeNewswire (Europe) | NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)... ► Artikel lesen | |
| 02.06.25 | MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients | 98 | GlobeNewswire (Europe) | NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 49,850 | -0,89 % | BB Biotech: Gewinnsprung 2025 und höhere Dividende geplant | Die BB Biotech AG hat für das Geschäftsjahr 2025 vorläufig einen Nettogewinn von 578 Millionen CHF ausgewiesen, nach 76 Millionen CHF im Vorjahr. Die Ergebnisse der Biotech-Beteiligungsgesellschaft... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,060 | -4,57 % | Viking Therapeutics: The Under-the-Radar GLP-1 Contender Growth Hunters Can't Ignore | ||
| NOVOCURE | 8,694 | -1,29 % | Novocure-Aktie stürzt ab: US-Gesundheitsbehörde entzieht Abrechnungsbefugnis | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,564 | -6,57 % | Oxford Nanopore Technologies: Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe | Oxford Nanopore has reached a major regulatory milestone with the registration of its first In Vitro Diagnostic ("IVD") device in the UK and Europe: the GridION Dx.
Oxford Nanopore Technologies... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,344 | +0,58 % | XFRA MAH0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BIOLINERX | 2,310 | +1,09 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| ASSERTIO | 11,630 | -0,43 % | Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split | LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,077 | 0,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| REVOLUTION MEDICINES | 81,00 | +0,62 % | Revolution Medicines, Inc.: Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor | REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced... ► Artikel lesen | |
| ROIVANT SCIENCES | 22,310 | -2,92 % | Roivant Sciences: Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 | Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (?21.6 PPriovant... ► Artikel lesen | |
| ARVINAS | 12,950 | -3,72 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| JANUX THERAPEUTICS | 13,120 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| WEREWOLF THERAPEUTICS | 0,686 | -3,94 % | Werewolf Therapeutics, Inc. - 8-K, Current Report | ||
| TRANSCODE THERAPEUTICS | 10,100 | -6,83 % | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 1,650 | -0,60 % | Silexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 | SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated... ► Artikel lesen |
MINK THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,550 Euro und damit +1,18 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.